Opendata, web and dolomites

NeuroPa SIGNED

Targeting the brain sigma-1 receptor: A paradigm shift for the treatment of neuro-degenerative disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeuroPa project word cloud

Explore the words cloud of the NeuroPa project. It provides you a very rough idea of what is the project "NeuroPa" about.

sigmathera    diseases    slow    addressable    qualities    urgent    tries    investor    alzheimer    safety    comparably    societies    company    biggest    sclerosis    data    clinical    fail    ad    repositioning    progression    lateral    aging    previously    neuropa    brain    speaking    regulatory    market    regulator    population    multiple    close    an    projected    peak    sit    trillion    pressing    suffering    positioning    euros    patent    treatment    2b    symptoms    effect    life    feasibility    drugs    candidates    disease    asset    provides    changing    severity    161    neurodegenerative    competing    muscle    profile    sales    spasms    drug    abandoned    strategy    million    proven    motor    compound    modifying    patients    protection    2018    french    impressive    receptor    full    original    reflected    treatments    critical    sigma    paralysis    worldwide    humans    als    neurodegeneration    candidate    depression    amyotrophic    swallowing    prevalent    total    excellent    orphan    pipeline    proof    efficacy    western    commercial    symptomatic    lethality    trials   

Project "NeuroPa" data sheet

The following table provides information about the project.

Coordinator
SIGMATHERA SAS 

Organization address
address: AGROPOLIS 2, 2196 BOULEVARD DE LA LIRONDE
city: MONTFERRIER SUR LEZ
postcode: 34980
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIGMATHERA SAS FR (MONTFERRIER SUR LEZ) coordinator 50˙000.00

Map

 Project objective

An increasingly aging population suffering from neurodegenerative diseases represents one of the biggest challenges for Western societies. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease with over 50 million patients worldwide and an estimated cost of 1 trillion euros in 2018. In addition, orphan neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) have a comparably urgent need for treatment, because of the severity and life changing effect of the motor symptoms (muscle spasms, speaking and swallowing problems, full paralysis and lethality). As current treatments are only symptomatic and fail to slow down the disease progression, there is a pressing need for novel effective disease-modifying treatments.

SigmaThera is a French company that tries to address the need for effective treatments for neurodegenerative diseases by focusing on the repositioning of drug candidates: applying the proven qualities of previously developed drugs for new diseases. For our lead compound SIT-161 with an excellent safety profile in humans (the candidate was abandoned after original Phase 2 trials for major depression) we have obtained impressive proof-of-concept data and patent protection for the treatment of neurodegenerative diseases, including AD & ALS. The drug targets a brain sigma-1 receptor, a critical regulator of multiple processes in neurodegeneration and provides unique efficacy and safety compared to other competing candidates in the pipeline. The high commercial potential of the drug is reflected in the €6.2B total addressable market and projected peak sales of €2B. In the NeuroPa project, SigmaThera will investigate market positioning, clinical and regulatory feasibility, future patent strategy and investor strategy to bring this promising asset close to market implementation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROPA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUROPA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

polyBioMetal (2019)

Polymer Biotechnological Metallization

Read More  

EHS (2019)

Thermo-adjustable endoscope heater system to solve problems of fogging during surgical interventions

Read More  

EDITUS (2019)

Helping our customers to design smart and safe tomorrows’ communication systems

Read More